Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 497Neoplasms 302Breast Neoplasms 294Colorectal Neoplasms 228Neoplasm Metastasis 194Prostatic Neoplasms 175Ovarian Neoplasms 173Lung Neoplasms 159Multiple Myeloma 158Recurrence 131Melanoma 125Pancreatic Neoplasms 115Squamous Cell Carcinoma of Head and Neck 104Stomach Neoplasms 102Leukemia, Myeloid, Acute 101Endometrial Neoplasms 101Small Cell Lung Carcinoma 88Leukemia, Lymphocytic, Chronic, B-Cell 87Triple Negative Breast Neoplasms 84Lymphoma, Non-Hodgkin 84Carcinoma, Renal Cell 83Carcinoma, Hepatocellular 79Urinary Bladder Neoplasms 77Lymphoma, Large B-Cell, Diffuse 74Lymphoma, Follicular 68Advanced Solid Tumors 66Lymphoma 62Parkinson Disease 4, Autosomal Dominant Lewy Body 61Glioblastoma 58Head and Neck Neoplasms 56

Interventions

enzalutamide 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Metastatic Hormone Sensitive Prostate Cancer × 90 days × Clear all
NCT04076059 2026-04-17

China ARCHES

Astellas Pharma Inc

Phase 3 Active not recruiting
180 enrolled 24 charts
Genitourinary

Metastatic Hormone Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡